Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with lenvatinib within its marketing authorisation for untreated PD-L1 positive metastatic non- small- cell lung cancer.
Status In progress
Process STA 2018
ID number 3809

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
12 March 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer. Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.
04 February 2021 - 04 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
03 March 2020 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance